DelveInsight’s latest report, “TIGIT Inhibitor Pipeline Insight 2026,” provides a comprehensive analysis of the rapidly evolving TIGIT inhibitor landscape. The study highlights the contributions of over 14 leading pharmaceutical and biotechnology companies developing more than 18 pipeline therapies targeting TIGIT, an emerging immune checkpoint in oncology.
The report offers detailed insights into both clinical and preclinical drug candidates, along with a thorough evaluation based on product type, development stage, route of administration, and molecular class. Additionally, it sheds light on discontinued and inactive programs, providing a complete view of the pipeline ecosystem.
Explore the latest updates in the TIGIT inhibitor pipeline and ongoing clinical trials: https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight
Key Highlights from the TIGIT Inhibitor Pipeline Report
Discover which companies are leading innovation in TIGIT-targeted therapies: https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight
Overview of TIGIT as a Therapeutic Target
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) has emerged as a promising immune checkpoint target in cancer immunotherapy. TIGIT is a transmembrane receptor expressed on activated T cells, natural killer (NK) cells, and regulatory T cells.
It interacts with ligands such as CD155 and CD112 on antigen-presenting cells, leading to immune suppression and reduced anti-tumor activity. Targeting TIGIT can help restore immune function, enhance T-cell activation, and improve NK cell-mediated tumor responses, making it an attractive approach in oncology drug development.
Emerging Drug Profiles in the TIGIT Inhibitor Space
Tiragolumab – Genentech
Tiragolumab is a monoclonal antibody designed to inhibit TIGIT by preventing its interaction with CD155. This blockade helps restore immune activity, particularly when combined with PD-L1 inhibitors, resulting in enhanced T-cell activation and improved anti-tumor responses.
Ociperlimab – BeiGene
Ociperlimab (BGB-A1217) is an investigational monoclonal antibody with high specificity for TIGIT. It blocks interactions with CD155 and CD112, thereby promoting T-cell-mediated immune responses against tumors. With an optimized Fc region, ociperlimab is among the most advanced anti-TIGIT therapies under development.
Stay updated on the latest TIGIT inhibitor clinical trials and drug developments: https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight
Comprehensive Pipeline and Therapeutic Assessment
The report delivers an in-depth analysis of the TIGIT inhibitor pipeline, including:
It also provides extensive information on strategic collaborations, licensing deals, mergers, acquisitions, and funding activities shaping the future of TIGIT-targeted therapeutics.
Key Companies in the TIGIT Inhibitor Landscape
Leading players contributing to the development of TIGIT inhibitors include Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, Merck KGaA, Curocell, Agenus, Compugen, Tasrif Pharmaceutical, Y-Biologics, Aurigene, Mereo BioPharma, Phio Pharmaceuticals, and Bio-Thera Solutions, among others.
Phases
DelveInsight’s report covers around 18+ products under different phases of clinical development like
Route of Administration
TIGIT Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Molecule Type
Products have been categorized under various Molecule types such as
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Scope of the TIGIT Inhibitor Pipeline Report
Gain a complete view of the TIGIT inhibitor pipeline and future opportunities: https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight
Strategic Insights and Future Outlook
The TIGIT inhibitor space represents one of the most promising areas in immuno-oncology, with increasing interest from both established pharmaceutical companies and emerging biotech firms. The growing focus on combination therapies, particularly with PD-1/PD-L1 inhibitors, is expected to unlock new therapeutic potential and improve patient outcomes.
As clinical trials progress and more data becomes available, TIGIT inhibitors are anticipated to play a significant role in the next generation of cancer immunotherapies.
Table of Contents
1. Introduction
2. Executive Summary
3. TIGIT Inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. TIGIT Inhibitors – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tiragolumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MK-7684A: Merck
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. M 6223: Merck
15. Drug profiles in the detailed report…..
16. Pre-clinical and Discovery Stage Products
17. TSRF 786C: Tasrif Pharmaceutical
18. Drug profiles in the detailed report…..
19. Inactive Products
20. TIGIT Inhibitors Key Companies
21. TIGIT Inhibitors Key Products
22. TIGIT Inhibitors- Unmet Needs
23. TIGIT Inhibitors- Market Drivers and Barriers
24. TIGIT Inhibitors- Future Perspectives and Conclusion
25. TIGIT Inhibitors Analyst Views
26. TIGIT Inhibitors Key Companies
27. Appendix
About DelveInsight
DelveInsight is a leading healthcare consulting and market research firm dedicated to the life sciences industry. The company provides high-quality market intelligence, competitive analysis, and strategic insights to help organizations make informed business decisions.
With deep expertise in healthcare and a global perspective, DelveInsight delivers customized solutions to support innovation and growth across pharmaceutical and biotech sectors.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting
